Doximity is expected to report Q3 2026 revenue of $170.84 million and GAAP EPS of $0.19, with the current stock price of $32.87 trading slightly above the average analyst price target of $31.80. Investors are primarily focused on verified user engagement metrics following a significant shareholder lawsuit alleging the company overstated its "deep engagement" and advertising effectiveness. This report is critical as management attempts to prove that recent investments in AI tools like DoxGPT are successfully offsetting a broader deceleration in pharmaceutical advertising spend. While revenue growth has slowed to a projected 1.4% year-over-year, the company's ability to maintain high margins through its physician workflow platform remains a key point of evaluation for Wall Street.